Key Highlights
- SK bioscience subscribes to Sunflower Therapeutics’ $2M SAFE agreement.
- Focus on developing cost-effective HPV vaccine using Pichia pastoris.
- Sunflower’s innovative continuous fermentation and Daisy PetalTM perfusion bioreactor.
- Enhanced vaccine manufacturing efficiency and accessibility.
Source: Business Wire
Notable Quotes
- “Our accessible, cutting-edge protein manufacturing solutions are moving the needle by reimagining the biologic development process.” — Dr. Kerry R. Love, Founder, CEO, and President at Sunflower Therapeutics
- “In this time where various infectious diseases threaten humanity, vaccine sovereignty is the key to protecting the safety of our people and enhancing national competition.” — Jaeyong Ahn, CEO at SK Bioscience
SoHC's Take
The collaboration between Sunflower Therapeutics and SK bioscience exemplifies the strategic partnerships necessary to revolutionize vaccine development and manufacturing. With SK bioscience’s $2M SAFE subscription, the focus on using Sunflower’s innovative biomanufacturing techniques, including continuous fermentation and the Daisy PetalTM perfusion bioreactor, positions both companies at the forefront of producing cost-effective and accessible vaccines. This partnership is a significant step toward democratizing healthcare and addressing public health crises like HPV and cervical cancer on a global scale.
